Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups

Булгакова, В.А.; Поромов, А. А.; Грекова, А. И.; Pshenichnaya, N.; Селькова, Е. П.; Львов, Н. И.; Leneva, I. A.; Shestakova, I.; Maleev, V V

doi:10.17116/terarkh201789162-71

Cited by 15 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients that were treated with Umifenovir (in the first 48 h after disease onset), the duration of fever and frequency of pneumonia proved to be lower than those in the patients who did not receive antiviral therapy. Umifenovir therapy substantially reduces the duration of fever and risk of complications, especially in patients with laboratory-confirmed influenza infection [25].…”

Section: Introductionmentioning

confidence: 99%

Antioxidant Potential of Antiviral Drug Umifenovir

et al. 2020

View full text Add to dashboard Cite

Free radical reactions play an important role in biological functions of living systems. The balance between oxidants and antioxidants is necessary for the normal homeostasis of cells and organisms. Experimental works demonstrate the role of oxidative stress that is caused by influenza virus as well as the toxic effects of some antiviral drugs. Therefore, antiviral drugs should be characterized by its pro-and antioxidant activity, because it can affect its therapeutic efficiency. The aim of the study was to quantify the antioxidant capacity and propose the mechanism of the antioxidant effect of the antiviral drug Umifenovir (Arbidol ® ). The kinetic chemiluminescence with the 2,2'-azobis (2-amidinopropane) dihydrochloride + luminol system was used to quantify the antioxidant capacity of Umifenovir relative to the standard compound Trolox. With computer simulation, the reaction scheme and rate constants were proposed. The antioxidant capacity of 0.9 µM Umifenovir (maximum concentration of Umifenovir in blood after oral administration of 200 mg) was as high as 1.65 ± 0.18 µM of Trolox. Thus, the total antioxidant capacity of Umifenovir is comparable to the antioxidant capacity of Trolox. Unlike Trolox, Umifenovir reacts with free radicals in two stages. For Trolox, the free radical scavenging rate constant was k = 2000 nM −1 min. −1 , for Umifenovir k 1 = 300 nM −1 min. −1 , k 2 = 4 nM −1 min. −1 . Slower kinetics of Umifenovir provides the prolonged antioxidant effect when compared to Trolox. This phenomenon can make a serious contribution to the compensation of oxidative stress that is caused by a viral disease and the therapeutic effect of the drug.

show abstract

Section: Introductionmentioning

confidence: 99%

Antioxidant Potential of Antiviral Drug Umifenovir

et al. 2020

View full text Add to dashboard Cite

show abstract

“…(provided that it was administered in the first 48 hours after disease onset), the duration of fever and frequency of complications proved to be lower than in patients who did not receive antiviral therapy in a study reported by Russian (Bulgakova et al, 2017). Reports in the literature and clinical data showed that arbidol was safe for elderly patients.…”

Section: Same As the Sixth Edition Yesmentioning

confidence: 86%

Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy

Ying

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Given the extreme importance of the current pandemic caused by COVID-19 and due to the fact that scientists agree that there is no identified treatment, this paper analyzes in detail the treatment of a severe COVID-19 patient with convalescent plasma and drugs based on current guidelines for COVID-19 diagnosis and treatment. This can provide a reference for other medical institutions on rational drug use and pharmaceutical care for severe COVID-19 patients.

show abstract

“…It was reported that the use of arbidol in patients over 65 years old reduced the incidence of nosocomial pneumonia, and adverse reactions associated with the arbidol were not identified in the study. 64 We suggest that elderly COVID-19 patients could use arbidol. Besides, arbidol is metabolized by CYP3A4, and ritonavir is a CYP3A inhibitor; therefore, a combination of ritonavir and arbidol may increase the arbidol serum concentration.…”

Section: Antiviral Agents In Elderly Covid-19 Patientsmentioning

confidence: 95%

<p>Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients</p>

Li¹,

Wang²,

Wang³

et al. 2020

DDDT

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.

show abstract

Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups

Cited by 15 publications

References 18 publications

Antioxidant Potential of Antiviral Drug Umifenovir

Antioxidant Potential of Antiviral Drug Umifenovir

Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy

<p>Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients</p>

Contact Info

Product

Resources

About